Biotech patents in 2026: align antibody claims with the experimental record

horak Rechtsanwälte · Patent insights and case law

English · Deutsch · Français

An antibody programme can generate valuable results long before the patent team has a coherent record of what was made, tested and disclosed. The difficulty is often the relationship between a promising candidate and the broader class the business wants to protect. A useful review connects claim language with experiments, supported alternatives and identifiable commercial products.

The 2026 examination context

The EPO’s 2026 Guidelines apply from 1 April 2026. The antibody sections address structural and functional definitions, including the ability to identify the claimed subject matter and reproduce functionally defined antibodies without undue burden. These references describe current examination guidance; they do not mean that every antibody rule changed this year. [1] [2] [3]

A different sequence is not, by itself, the complete inventive-step case. The Guidelines discuss technical effects and difficulties relevant to that assessment. [4] Separately, G 2/21, decided on 23 March 2023, addresses reliance on a technical effect and later evidence for inventive step. It is not a general permission to repair every disclosure gap with new experiments. [5]

Turn laboratory information into a reviewable file

Create a table connecting each candidate with its sequence identifier, construct, assay and result. Keep the actual protocol version and identify changes in concentration, controls, equipment and interpretation criteria. A graph detached from these details may be commercially persuasive but difficult to assess in examination or opposition. Ask scientists to identify what an assay establishes and what it does not establish about the claimed property.

Bring patent and research teams together before selecting a claim strategy. Discuss the difference between a particular molecule, a defined family and a functionally described group. Identify the supporting disclosure for proposed alternatives and the work needed to produce them. Keep the application as filed separate from later research reports so reviewers can see which information existed at each stage, rather than inadvertently combining everything into one undated narrative.

Plan the commercial and litigation review together

Map the intended claim to the product under development and plausible manufacturing changes. For a transaction, distinguish the evidence supporting ownership from the evidence supporting scientific performance. For a dispute, identify which samples, protocols and witnesses could establish the relevant facts. A laboratory team should not first learn of an important preservation requirement when a key researcher is leaving or a supplier contract is ending.

Confidentiality needs practical arrangements: document access, sample handling and responsibility for external testing. Coordinate these arrangements with counsel before disclosure to a counterparty. The objective is an evidence file that can be explained and, where appropriate, scrutinised, without treating every research document as automatically relevant or automatically safe to disclose.

Four practical examples

1. Two assays produce different classifications

A candidate meets a functional threshold under one protocol but not another. The team compares conditions and records why the results differ. Counsel can then assess the wording used to define the property rather than relying on the most favourable graph alone.

2. A broad family rests on a few candidates

Researchers have tested three molecules while the proposed commercial protection covers many variants. The review identifies the evidence supporting the wider class and the uncertainties that remain. Drafting decisions are made against that record, not a sales forecast.

3. A later experiment supports a disputed effect

After filing, a new study strengthens an effect asserted for inventive step. Counsel connects the argument to the original disclosure and evaluates the later evidence under the applicable framework. The study is not treated as rewriting the original application.

4. A manufacturing partner changes a key record system

A partner plans to replace its laboratory database. Before migration, the project team preserves relevant records, metadata and links to physical samples. This makes later reconstruction less dependent on the memory of individual scientists or a discontinued software platform.

Practical guide reviewed on 17 November 2026. The examples are hypothetical and do not describe client matters.

Official sources

1. https://www.epo.org/en/news-events/news/guidelines-2026-enter-force-streamlining-procedural-guidance

2. https://www.epo.org/en/legal/guidelines-epc/2026/g_ii_6_1_1.html

3. https://www.epo.org/en/legal/guidelines-epc/2026/g_ii_6_1_3.html

4. https://www.epo.org/en/legal/guidelines-epc/2026/g_ii_6_2.html

5. https://www.epo.org/en/legal/official-journal/2023/09/a85

Discuss your patent matter

Please identify the patent, the affected product and any known deadline. Do not send confidential technical details before conflicts have been checked. Contact our team